23andMe CEO on the future of genomics The Human Genome Task, completed in 2003, single-handedly transformed science and medicine. Because of DNA sequencing technology we are learning more about human wellness than ever before, attaining insight into complex illnesses and unlocking mysteries about individual evolution and ancestry. Anne Wojcicki, founder and CEO of 23andMe, is among the pioneers in the booming genomics market read . Wojcicki’s organization was the first ever to bring genetic examining to the house frontier with her direct-to-customer DNA testing kits. While 23andMe has run into its fair talk about of challenges, the business seeks to empower the public and change the real way we think about our health and wellness and genetic makeup.
Among 15 ROS1 FISH-positive tumors examined for MET amplification by using FISH, 1 was positive, with a MET-to-CEP7 ratio of 5.34, whereas the remaining 14 were negative. . The entire response rate was 72 percent . The median period to the first response was 7.9 weeks . At the time of data cutoff, 23 of the 36 responses were ongoing . The approximated median duration of response was 17.six months . Three of the 50 patients had proof progressive disease on the first restaging scans. For 1 of the 3 patients, results on FISH were atypical, and next-generation sequencing was detrimental for ROS1 rearrangement, as noted above.